Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Oct;55(10):4552-9.
doi: 10.1128/AAC.00157-11. Epub 2011 Aug 1.

Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes

Affiliations

Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes

Kendra E Hightower et al. Antimicrob Agents Chemother. 2011 Oct.

Abstract

The integrase inhibitor (INI) dolutegravir (DTG; S/GSK1349572) has significant activity against HIV-1 isolates with raltegravir (RAL)- and elvitegravir (ELV)-associated resistance mutations. As an initial step in characterizing the different resistance profiles of DTG, RAL, and ELV, we determined the dissociation rates of these INIs with integrase (IN)-DNA complexes containing a broad panel of IN proteins, including IN substitutions corresponding to signature RAL and ELV resistance mutations. DTG dissociates slowly from a wild-type IN-DNA complex at 37°C with an off-rate of 2.7 × 10(-6) s(-1) and a dissociative half-life (t(1/2)) of 71 h, significantly longer than the half-lives for RAL (8.8 h) and ELV (2.7 h). Prolonged binding (t(1/2), at least 5 h) was observed for DTG with IN-DNA complexes containing E92, Y143, Q148, and N155 substitutions. The addition of a second substitution to either Q148 or N155 typically resulted in an increase in the off-rate compared to that with the single substitution. For all of the IN substitutions tested, the off-rate of DTG from IN-DNA complexes was significantly slower (from 5 to 40 times slower) than the off-rate of RAL or ELV. These data are consistent with the potential for DTG to have a higher genetic barrier to resistance, provide evidence that the INI off-rate may be an important component of the mechanism of INI resistance, and suggest that the slow dissociation of DTG may contribute to its distinctive resistance profile.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
HIV-1 integrase inhibitors. (A) Dolutegravir (DTG; S/GSK1349572); (B) raltegravir (RAL); (C) elvitegravir (ELV).
Fig. 2.
Fig. 2.
DTG dissociation from wild-type IN-DNA-bead complex at 37°C. Signal in the absence (●) or presence (○) of excess unlabeled DTG following subtraction of the appropriate nonspecific binding control. Bkgr, background; ADU, analogue to digital units.
Fig. 3.
Fig. 3.
INI dissociation from selected IN-DNA complexes. Symbols are the same for all graphs and represent DTG (●), RAL (○), and ELV (▼). IN-DNA complexes contained wild type (WT) IN (A), Y143R IN (B), Q148H IN (C), or N155H IN (D).
Fig. 4.
Fig. 4.
Statistical analysis of INI off-rates from IN-DNA complexes. An analysis of variance model was fit to relate the log-transformed koff values to the inhibitors and proteins. Statistical comparisons were performed, and the resulting P values were calculated using this model. The symbols represent the koff estimate and 95% confidence intervals for each IN-DNA complex containing the indicated IN protein (3 to 8 independent koff values were generated for each INI with each IN-DNA complex). For each INI, the koff values for complexes with the IN substitutions were different (P < 0.05) from the wild type (WT) except where noted (*).
Fig. 5.
Fig. 5.
Comparison of dissociative half-life and in vitro antiviral activity. The fold change data were previously reported (30). Symbols represent DTG (●), RAL (○), and ELV (▾). The horizontal line indicates the threshold for resistance that was determined in the cell-based study (FC ≥ 3).

Similar articles

Cited by

References

    1. Asante-Appiah E., Skalka A. M. 1999. HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv. Virus Res. 52:351–369 - PubMed
    1. Boros E. E., Johns B. A., Garvey E. P., Koble C. S., Miller W. H. 2006. Synthesis and HIV-integrase strand transfer inhibition activity of 7-hyroxyl[1,3]thiazolo[5,4-b]pyridin-5(4H)-ones. Bioorg. Med. Chem. Lett. 16:5668–5672 - PubMed
    1. Ceccherini-Silberstein F., et al. 2009. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev. 11:17–29 - PubMed
    1. Chiu T. K., Davies D. R. 2004. Structure and function of HIV-1 integrase. Curr. Top. Med. Chem. 4:965–977 - PubMed
    1. Cooper D. A., et al. 2008. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 359:355–365 - PubMed

MeSH terms